(R3) Podium Session – Award-winning Research Supporting the Managed Care Pharmacy Research Agenda

AMCP and the AMCP Foundation jointly developed a Managed Care Pharmacy Research Agenda to inspire research in high-priority areas with a significant potential to improve health care quality – for all. The agenda identified for research pillars: (1) real-world evidence to inform managed care pharmacy decision-making, (2) value-based models in managed care pharmacy to address the total cost of care, (3) impact of benefit design or utilization management strategies on patient outcomes, and (4) impact of direct patient care services provided by managed care pharmacy on patient outcomes.

In this podium session, authors of the top-rated abstracts aligned to each of these research pillars will present and discuss their findings.

The platinum abstract award presentations are:

• Identification and management of duplicate therapy involving incretin-targeting therapies for diabetes and weight loss

• Specialty drug use varies by race and wage among employees with employer-sponsored health insurance

• Making the cut: a review of evidence trends in the Institute for Clinical and Economic Review’s unsupported price increase reports

• Evaluating the impact of the Inflation Reduction Act (IRA) $2,000 out-of-pocket spending cap on Medicare Part D beneficiaries

At the end of this presentation, participants will be able to:
• Describe the overlapping mechanisms of action and clinical considerations associated with a combination GLP-1 agonist and DPP-IV inhibitor (both incretin mimetics) drug therapy.
• Explain how a managed care pharmacist clinical program focused on requesting the prescriber stop duplicate incretin mimetic therapy can effectively contain payer costs while optimizing member therapy.
• Compare race/ethnicity and wage status on specialty prescription use and adherence patterns among employees with autoimmune conditions (AICs) who enrolled in employer-sponsored health insurance.
• Indicate the potential to yield more equitable health outcomes in these subpopulations within their organizations.
• Describe two types of trends for ICER’s Unsupported Price Increase (UPI) reports: (1) manufacturers’ evidence submissions and (2) ICER’s evidence determinations.
• Discuss the impact of the Inflation Reduction Act (IRA) $2,000 Out-of-Pocket Spending Cap on Medicare Part D Beneficiaries.